ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

2:00PM-3:30PM: Abstract Number: 0765

RheumMadness and TheMednet: The Impact of a Collaboration Between Independent Educational Initiatives

Abstracts: Professional Education

2:00PM-3:30PM: Abstract Number: 0743

Risk and Temporal Trends of Heart Failure Subtypes in Rheumatoid Arthritis: A National Veterans Affairs Matched Cohort Study

Abstracts: Epidemiology & Public Health I

2:00PM-3:30PM: Abstract Number: 0742

Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes

Abstracts: Epidemiology & Public Health I

2:00PM-3:30PM: Abstract Number: 0729

ROCK1 Orchestrates B-cell Differentiation Under Stress

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease

2:00PM-3:30PM: Abstract Number: 0732

Should Complete B-cell Depletion Be Maintained in Patients Treated Long-term with Rituximab for Rheumatoid Arthritis?

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease

2:00PM-3:30PM: Abstract Number: 0792

Single Cell RNA-seq of Myeloid Cells from Systemic Sclerosis Patients Identifies Circulating Monocyte Population with Interferon Signature Associated with Interstitial Lung Disease

Abstracts: Systemic Sclerosis & Related Disorders I: Translational

2:00PM-3:30PM: Abstract Number: 0773

Sputum Lautropia Abundance Is Decreased in Rheumatoid Arthritis-Associated Pulmonary Fibrosis and Correlates with Lung Disease Severity

Abstracts: RA – Diagnosis, Manifestations, & Outcomes I: RA-ILD

2:00PM-3:30PM: Abstract Number: 0763

Sticking the Landing: A 3-Year Qualitative Longitudinal Study on Navigating Transitions in Pediatric Rheumatology Fellowship

Abstracts: Professional Education

2:00PM-3:30PM: Abstract Number: 0728

Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease

2:00PM-3:30PM: Abstract Number: 0789

Telomere Length of Peripheral Blood Cells Predicts More Severe Pulmonary Disease and Worse Survival in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders I: Translational

2:00PM-3:30PM: Abstract Number: 0746

The Association Between Sonographic Imaging Phenotype and Response to Treatment in Patients with Psoriatic Arthritis

Abstracts: Imaging of Rheumatic Diseases

2:00PM-3:30PM: Abstract Number: 0778

The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA

2:00PM-3:30PM: Abstract Number: 0766

The OMERACT GCA Phantom Project: Validation of 3D Printed Ultrasound Training Models for Giant Cell Arteritis

Abstracts: Professional Education

2:00PM-3:30PM: Abstract Number: 0785

Therapeutic Range of Hydroxychloroquine Blood Levels May Reduce Odds of High Lupus Disease Activity

Abstracts: SLE – Treatment I: Renal

2:00PM-3:30PM: Abstract Number: 0783

Tolerability of CAR T Cell Therapy in Autoimmune Disease

Abstracts: SLE – Treatment I: Renal

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].